| Pharmaceutical Information |
| Drug Name |
Travoprost |
| Drug ID |
BADD_D02265 |
| Description |
Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure [FDA Label]. It is a synthetic prostaglandin F2alpha analog [FDA Label]. Having been a well-received therapeutic agent with demonstrated efficacy and safety, travoprost is currently approved by the US FDA as a first-line treatment for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypotension [L5155]. Furthermore, this approval also solidifies the medication as the first and only prostaglandin analog approved by the FDA for first-line treatment of glaucoma patients that does not contain the preservative benzalkonium chloride [L5155]. Moreover, travoprost is also currently approved in the EU for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146, L5152]. |
| Indications and Usage |
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension [F3061, F3064, L5146].
Travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146]. |
| Marketing Status |
approved |
| ATC Code |
S01EE04 |
| DrugBank ID |
DB00287
|
| KEGG ID |
D01964
|
| MeSH ID |
D000069557
|
| PubChem ID |
5282226
|
| TTD Drug ID |
D09CZA
|
| NDC Product Code |
82231-114; 54893-0020; 63190-0350; 63629-8840; 61556-040; 64181-0028; 51407-731; 60505-0593; 63629-8839; 24002-0022; 65035-131; 68245-0003; 0781-6185; 40016-006; 0078-0946; 55359-540; 65129-1207 |
| UNII |
WJ68R08KX9
|
| Synonyms |
Travoprost | Travatan Z | Z, Travatan | Travatan | (((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester | AL-6221 | AL 6221 | AL6221 |
|
| Chemical Information |
| Molecular Formula |
C26H35F3O6 |
| CAS Registry Number |
157283-68-6 |
| SMILES |
CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC(=C2)C(F)(F)F)O)O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
